{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:07:32Z","timestamp":1768442852149,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Several risk mitigation steps have improved the safety of platelets in regard to bacterial contamination, but this continues to be a concern today. A Food and Drug Administration (FDA) Guidance issued in December 2018 aims to further limit this risk. The guidance offers multiple pathways for compliance, and hospital blood banks will have to collaborate with blood donor centers to assess various factors before deciding which method is most appropriate for them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and materials<\/jats:title><jats:p>Our institution considered several factors before moving forward with pathogen reduction technology. This included an assessment of platelet shelf\u2010life, bacterial testing requirements, the efficacy of low\u2010yield platelets, and managing a mixed platelet inventory. The decision to transition to pathogen\u2010reduced platelets was associated with complex collection and processing limitations that resulted in either an increase in platelets that were over\u2010concentrated or products with a low platelet yield.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Through trials of various collection settings with unique target volumes and target platelet yields, our blood donor center was able to optimize the production. At the hospital end, this transition required a thorough review of low\u2010yield platelet products and their clinical efficacy. Additionally, this implementation necessitated collaboration with clinical colleagues, comprehensive education, and training.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pathogen\u2010reduced platelets would be the most efficient way for our institution to be compliant. This summary may serve as a roadmap for other institutions that are considering which FDA prescribed method to use and provide support for those that have decided on pathogen reduction technology but need to optimize their collections to best utilize low\u2010yield products.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16744","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T13:15:50Z","timestamp":1637327750000},"page":"3295-3302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How do I implement pathogen\u2010reduced platelets?"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-0289","authenticated-orcid":false,"given":"Tho D.","family":"Pham","sequence":"first","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Stanford Blood Center Stanford University  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7441-268X","authenticated-orcid":false,"given":"Wendy","family":"Kadi","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Shu","sequence":"additional","affiliation":[{"name":"Stanford Blood Center Stanford University  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-2353","authenticated-orcid":false,"given":"Suchitra","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Stanford Blood Center Stanford University  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Sussmann","sequence":"additional","affiliation":[{"name":"Stanford Blood Center Stanford University  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3764-1787","authenticated-orcid":false,"given":"Hua","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-2090","authenticated-orcid":false,"given":"Mrigender S.","family":"Virk","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Fatalities reported to FDA following blood collection and transfusion annual summary for FY2019."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_7_4_1","unstructured":"United States Food and Drug AdministrationBacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. Released 2020 Dec 17. Accessed 17 Dec 2020.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/bacterial\u2010risk\u2010control\u2010strategies\u2010blood\u2010collection\u2010establishments\u2010and\u2010transfusion\u2010services\u2010enhance"},{"key":"e_1_2_7_5_1","first-page":"1","volume-title":"INTERCEPT blood system for platelets \u2010 Dual storage(DS) processing set","author":"Cerus","year":"2016"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4443"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12287"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15951"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02151.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12456"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12489"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.285.285"},{"issue":"10","key":"e_1_2_7_13_1","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"10","author":"Estcourt LJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15036"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16561"},{"key":"e_1_2_7_16_1","first-page":"45","volume-title":"Standards for blood banks and transfusion services","author":"American Association of Blood Banks","year":"2020"}],"updated-by":[{"DOI":"10.1111\/trf.16885","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000}}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T03:28:58Z","timestamp":1714620538000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/trf.16744"],"URL":"https:\/\/doi.org\/10.1111\/trf.16744","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/trf.16885","asserted-by":"object"}]},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"2021-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}